Endo-205 and Endometriosis: Promise, Limits, and Questions — Part 4

Watch the original video on TikTok

Full transcript of the original video, lightly edited for readability.

Probably not equally, and that matters. Fifth limitation. Endometriosis is heterogeneous. There is not one endometriosis. There are superficial lesions, deep infiltrating lesions, ovarian endometriomas, adenomyosis overlap, amongst others. And now we also have to include metabolic phenotypes. Glycolytic lesions, oxphs, heavy lesions, mixed lesions, lactate producing pockets, lactate consuming pockets, hypoxic cores, vascularized edges. So when we say Endo-205 targets abnormal P H. And beta catenin signaling, we need to ask, do all lesions have the same P H? Are all lesions as accessible for peptide delivery?

Do all lesions rely entirely on beta catenin accumulation? Do all lesions rely on glycolysis? Do some lesions rely heavily on OX post? Do mixed lesions create partial response? Do the most invasive cells sit in acidic regions or oxygenated regions? Do all patients express the same disease biology? Probably not. That does not mean the therapy is useless. It means patient selection may matter. Lesion phenotype may matter. Imaging may matter. Metabolic biomarkers may matter. Adjuvant therapy may be crucial. If the peptide truly stays lesion selective, then the risk may be controlled.

But if systemic exposure reaches other WNT. Active tissues, we need to know what happens. That is not fear mongering. That is basic biology. The same pathway that makes the drug powerful is also the pathway that demands caution. Seventh limitation. Endometriosis. Pain is not only lesion survival. This is very important. Endo-205 may target lesion biology. That is exciting. But endo warriors often suffer from pain that is also driven by mast cells, prostaglandins, nerve growth factor, substance P, central sensitization, pelvic floor dysfunction, adhesions, bladder involvement, bowel involvement, and neuroimmune amplification.

So even if Endo-205 reduces lesion activity, the question remains, does it reverse establish nerve sensitization? Does it affect mast cell driven pain? Does it help fibrosis? Does it help adhesions? Does it help adenomyosis? Does it help patients whose pain is no longer directly proportional to lesion burden? These are real concerns because one of the most painful lessons in endometriosis is that removing or suppressing lesions does not always remove the entire pain network. That does not make Endo-205 less important. It just means we have to be mature about what it may and may not solve.

Now here is where I think Endo Warriors should be both hopeful and grounded. Endo 2:05 may not be the final answer, but it represents the right kind of question. It asks, what is biologically different about the lesion? What weakness can we exploit? Can we avoid suppressing the entire endocrine system? Can we preserve fertility? Can we avoid medical menopause? Can we target disease mechanisms instead of simply masking symptoms? That is the paradigm shift. That is what matters, because women with endometriosis have been forced to live inside a medical model that often treats their body like the problem.

Too much estrogen, too much pain, too much emotion, too much Complexity. Too many symptoms. But end of 2:05 points toward a different model. The woman is not the problem. The lesion biology is the problem. The broken microenvironment is the problem. The abnormal signaling is the problem. The inflammatory terrain is the problem. The failure of clearance is the problem. The fibrosis and neuro immune loop is the problem. And once you understand that, everything changes. Because now the goal is no longer how do we shut her down?

The goal becomes how do we expose the lesions weakness. That is why Endo 2:05 matters. Not because it is guaranteed to work, not because it is magic, not because phase 1 means victory, but because it shows that endometriosis research is finally moving away from the lazy explanation of just suppress estrogen and toward a more intelligent model of disease biology. So when someone says Endo 2:05 is the future of endometriosis, I would say maybe. But let's prove it. Show us the human data.

Show us lesion regression. Show us pain outcomes. Show us fertility outcomes. Show us recurrence outcomes. Show us safety. Show us delivery. Show us which lesion types respond. Show us what happens after treatment stops. Because ender warriors have been promised relief before. They have been told this will help before. They have been handed drugs before. Because if Endo-205 works the way the mechanism suggests, it could be a major step toward non hormonal, lesion directed and endometriosis care. But if Endometriosis lesions are metabolically mixed with acidic glycolytic pockets and less acidic ox post driven survival pockets.

Then Endo-205 may need more than a beautiful mechanism. It may need proof that the peptide reaches enough of the lesion to matter. It may need proof that pH dependent entry does not leave behind the very cells capable of rebuilding the disease. It may need proof that metabolic flexibility does not become the escape route. And that is why the conversation cannot stop at Endo-205 targets acidic lesions. The real conversation is which parts of the lesion are acidic, which parts are oxidative, which parts are mixed?

Which cells survive? And do those surviving cells drive recurrence? Because even if Endo-205 does not become the final answer, it still teaches the field something that we have been preaching over the last seven years. Endometriosis is not just an estrogen disease. It's not just a surgically managed disease. It's past pain. It's a biologically intelligent, metabolically flexible, immune protected, signal driven lesion survival disease. And the future belongs to the people willing to target that machinery.